MedPath

Results of Glucose-6-phosphate Dehydrogenase Deficiency Screening Relate with Cost of Phototherapy in Neonatal Hyperbilirubinemia; A Randomized Controlled Trial

Phase 4
Completed
Conditions
Glucose-6-phosphate dehydrogenase deficiency (G6PD deficiency) is one of risk factors that should decrease the phototherapy threshold to be lower than G6PD-normal neonates.
hyperbilirubinemia, phototherapy, G6PD deficiency, neonate, screening
Registration Number
TCTR20220705006
Lead Sponsor
/A
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Completed
Sex
All
Target Recruitment
241
Inclusion Criteria

1. Neonates born at 35 or more weeks' gestation, 2. Born in Burapha University Hospital

Exclusion Criteria

Born before before obtain inform consent

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Cost of phototherapy 14 days after birth Hospital cost
Secondary Outcome Measures
NameTimeMethod
Incidence of G6PD deficiency 14 days after birth Cord blood G6PD screening
© Copyright 2025. All Rights Reserved by MedPath